Association of circulating tumor cells (CTCs) with immune checkpoint inhibitor (ICI) responses in metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Zhang, T. [1 ]
Poellmann, M. [2 ]
Park, S-J. [2 ]
Bu, J. [2 ]
Zhao, R. [1 ]
Zhou, Q. [1 ]
Agarwal, A. [3 ]
Parks, J. [4 ]
Reyes-Martinez, M. [4 ]
Armstrong, A. J. [5 ]
George, D. J. [4 ]
Wang, A. Z. [6 ]
Hong, S. [2 ]
机构：
[1] UTSW Univ Texas Southwestern Med Ctr, Internal Med, Dallas, TX USA
[2] Univ Wisconsin, Pharmaceut Sci, Madison, WI USA
[3] Univ North Carolina Chapel Hill, Sch Med, Chapel Hill, NC USA
[4] Duke Univ Med Ctr, Duke Canc Ctr, Med, Durham, NC USA
[5] Duke Canc Ctr, Med, Durham, NC USA
[6] UTSW Univ Texas Southwestern Med Ctr, Radiat Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1475P
引用
收藏
页码：S1221 / S1221
页数：1
相关论文
共 50 条
  • [31] Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration.
    Ravi, Praful
    Mantia, Charlene
    Su, Christopher
    Sorenson, Karl
    Rathi, Nityam
    Bakouny, Ziad
    Agarwal, Neeraj
    Costello, Brian Addis
    McKay, Rana R.
    Narayan, Vivek
    Alva, Ajjai Shivaram
    McGregor, Bradley Alexander
    Gao, Xin
    McDermott, David F.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma (mRCC).
    Zengin, Zeynep Busra
    Dizman, Nazli
    Salgia, Nicholas
    Jones, Jeremy
    Zhang, Jingbo
    Liu, Yunchao
    Xu, Bing
    Li, Fuwei
    Wang, Yan
    Li, Mengjian
    Du, Rong
    Zhou, Ye
    Hsu, Joann
    Salgia, Meghan
    Yang, Lixin
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma
    Grigg, Claud
    Sha, Wei
    Bose, Rupali
    Neelands, Brittany
    Brown, Landon Carter
    Matulay, Justin T.
    Clark, Peter E.
    Burgess, Earle F.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
    Perimbeti, Stuthi
    Jiang, Changchuan
    Deng, Lei
    Roy, Arya
    Gopalakrishnan, Keerthy
    Chatta, Gurkamal S.
    George, Saby
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [35] BODY COMPOSITION MAY BE PROGNOSTIC AND PREDICTIVE OF CLINICAL OUTCOMES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (ICI)
    Martini, Dylan
    Olsen, T. Anders
    Goyal, Subir
    Liu, Yuan
    Evans, Sean
    Magod, Benjamin
    Brown, Jacqueline
    Yantorni, Lauren
    Russler, Greta
    Caulfield, Sarah
    Goldman, Jamie
    Nazha, Bassel
    Harris, Wayne
    Kucuk, Omer
    Carthon, Bradley
    Master, Viraj
    Bilen, Mehmet
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A26 - A27
  • [36] Impact of corticosteroid (CS) exposure on acquired resistance to immune checkpoint inhibitor (ICI) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC): A single centre experience.
    Cheruvu, Sowmya
    Marandino, Laura
    Gutierrez, Ana
    Le, Ha Mo Linh
    Bravi, Carlo Andrea
    Rosero, Diana I.
    Hogan, Nalinie Joharatnam
    Mcmahon, David
    Cazzaniga, Walter
    Larkin, James
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL)
  • [37] Primary resistance (PrR) versus acquired resistance (AcR) to immune checkpoint inhibitors (ICI) in first-line metastatic renal cell carcinoma (mRCC)
    Guida, A.
    Silva, C. Alves Costa
    Colomba-Blameble, E.
    Flippot, R.
    Salviat, F.
    Bracarda, S.
    Escudier, B.
    Albiges, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S570 - S570
  • [38] Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI)
    Nuzzo, P. V.
    Adib, E.
    Weise, N.
    Curran, C.
    Stewart, T.
    Freeman, D.
    Nassar, A. H.
    Abou Alaiwi, S.
    Bakouny, Z.
    McGregor, B. A.
    Choueiri, T. K.
    Jain, R. K.
    Mckay, R. R.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S702 - S703
  • [39] Association of intra-tumoral microbiome and response to immune checkpoint inhibitors (ICIs) in patients with metastatic renal cell carcinoma (mRCC).
    Meza, Luis A.
    Choi, Yongwook
    Govindarajan, Ameish
    Dizman, Nazli
    Zengin, Zeynep Busra
    Hsu, Joann
    Salgia, Nicholas
    Salgia, Sabrina
    Malhotra, Jasnoor
    Chawla, Neal Shiv
    Chehrazi-Raffle, Alex
    Muddasani, Ramya
    Castro, Daniela V.
    Chan, Agnes
    Zhang, Guangfa
    Byron, Sara A.
    Highlander, Sarah K.
    Schork, Nick
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Metastatic renal cell carcinoma (MRCC): Responses to different immunotherapies
    Landonio, G
    Baiocchi, C
    Ferrari, M
    Gottardi, O
    Majno, M
    Scanzi, F
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 468 - 468
12345